Search results for "Highlights"


 
Results 11 - 20 of about 51 for "Highlights".

Beta-blockers linked to better outcomes in some patients with cirrhosis

Decompensation-free survival improved in patients with cirrhosis and portal hypertension who received beta-blockers versus placebo, largely due to a decrease in ascites.
April 2019

Statins associated with lower risk for postcolonoscopy colorectal cancer

The primary outcome of the retrospective cohort study was postcolonoscopy colorectal cancer within three years, defined as colorectal cancer diagnosed within six and 36 months after negative findings on index colonoscopy.
March 2019

Halting one ulcerative colitis treatment after escalating to new drug may be feasible, study finds

Patients with ulcerative colitis treated with 5-aminosalicylates who require escalation to anti-tumor necrosis factor-alpha (anti-TNF) therapy may be able to safely discontinue the first drug.
November 2018

Highlights

Based on the results, study authors suggested expanding colorectal cancer (CRC) screening to patients 45 years of age, but an accompanying editorial expressed concern that the risks could outweigh the benefits in the general population.
July 2019

Anticoagulants safe, effective in cirrhosis with portal vein thrombosis, review finds

Researchers analyzed eight studies with 353 patients to assess the effect of low-molecular-weight heparin or warfarin on recanalization, thrombosis progression, and bleeding.
May 2017

Probiotics reduce C. difficile in hospitalized patients on antibiotics, review finds

In 19 randomized controlled trials of 6,261 hospitalized patients on antibiotics, the incidence of C. difficile was 1.6% among patients taking probiotics compared to 3.9% in controls.
February 2017

Highlights

Mean procedure time per lesion was significantly shorter with cold snare polypectomy and anticoagulants, whereas the mean hospitalization period was longer in patients receiving hot snare polypectomy and heparin bridging.
July 2019

Keeping tabs

Highlights from the conference, held this past week in San Diego, included new research and clinical tips on stopping Barrett's esophagus surveillance, diet and environmental risk factors in patients with
May 2019

Efficacy, safety of second-line therapies analyzed for two types of IBS

A systematic review and network meta-analysis focused on alosetron, eluxadoline, ramosetron, and rifaximin in adult patients who had irritable bowel syndrome (IBS) with diarrhea or mixed stool.
April 2019

Combination therapy for IBD carries higher infection risk than monotherapy

Monotherapy for inflammatory bowel disease (IBD) with an immunosuppressive agent was associated with a lower risk of serious infection than a tumor necrosis factor (TNF) antagonist alone or an anti-TNF plus an immunosuppressive agent, according to a
March 2019

Result Page: Prev   1   2   3   4   5   Next